Xeris Biopharma Holdings, Inc. (XERS) Balance Sheet

The balance sheet has expanded significantly, driven by a major debt increase in 2026Q2, likely from a convertible note issuance. This has boosted cash reserves to $121.7M, but also introduced substantial leverage. The trajectory suggests a deliberate move to fund growth, though it raises the stakes for execution.

The debt increase appears strategic, likely to fund operations and provide a cash buffer, but it has pushed equity negative. With negative equity, the D/E ratio is not meaningful, but the absolute debt level is high relative to assets. Investors should monitor the terms and maturity of this debt, as refinancing risk could emerge if cash flows falter.

The asset base is dominated by cash and intangibles, consistent with a biotech model. Goodwill has remained constant, suggesting no impairments, but the lack of tangible assets means the balance sheet is sensitive to cash burn. The minimal PP&E underscores the asset-light nature, which supports the positive FCF trend seen in cash flow statements.

The negative equity is driven by massive retained earnings deficits, which have grown despite operational improvements. The $31.1M net loss in 2026Q2, including high SBC, has eroded equity further. This suggests that while the company is approaching breakeven, it remains dependent on external financing to sustain its balance sheet.

The cash position is strong, but the current ratio decline suggests that current liabilities have grown faster than current assets, likely due to the new debt. With operating cash flow turning positive, the company appears to have adequate liquidity for near-term needs, but the debt load increases the risk of a cash crunch if revenue growth stalls.